Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
1. Pemvidutide receives FDA's Fast Track designation for Alcohol Use Disorder. 2. RECLAIM trial for pemvidutide is currently enrolling patients. 3. 28 million adults in the U.S. have Alcohol Use Disorder. 4. Only 2% of patients receive treatment today, creating a significant treatment gap. 5. Pemvidutide may target comorbidities associated with AUD, enhancing its market potential.